Platelet-rich plasma induces mixed osteogenic/osteoclastogenic phenotype in osteosarcoma SaOS-2 cells: Role of TGF-beta

Current Pharmaceutical Biotechnology

Volumn 15, Issue 2, 2014, Pages 120-126

  Martinotti, Simona ^a   Mazzucco, Laura ^b   Balbo, Valeria ^b   Patrone, Mauro ^a   Mozzati, Marco ^c   Ranzato, Elia ^a   Burlando, Bruno ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b SS Antonio e Biagio General Hospital   (Italy)

^c Studio Medico Odontoiatrico Siom srl   (Italy)

Author keywords

Bone resorption; Osteogenesis; PRP; QPCR; SaOS 2; TGF 1

Indexed keywords

4 [4 (1, 3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL] BENZAMIDE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALIZARIN RED S; ALKALINE PHOSPHATASE; CATHEPSIN K; FIBROBLAST GROWTH FACTOR 1; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN C; TRANSCRIPTION FACTOR RUNX; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BETA ACTIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; 1,3 DIOXOLANE DERIVATIVE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; MESSENGER RNA;

ARTICLE; BONE DEFECT; BONE DEVELOPMENT; BONE MINERALIZATION; CALCEIN-AM ASSAY; CELL CULTURE; CELL MOTILITY; CHEMOTAXIS ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; PHENOTYPE; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAOS 2 CELL LINE; THROMBOCYTE RICH PLASMA; CELL MIGRATION; CONCENTRATION RESPONSE; UPREGULATION; BONE TUMOR; CELL MOTION; CHEMOTAXIS; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ALKALINE PHOSPHATASE; BENZAMIDES; BONE NEOPLASMS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOTAXIS; DIOXOLES; GENE EXPRESSION; HUMANS; OSTEOGENESIS; OSTEOSARCOMA; PHENOTYPE; PLATELET-RICH PLASMA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 84928404716     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140604121407     Document Type: Article

References (46)

1. Mazzucco, L.; Balbo, V.; Guaschino, R. Reasonable compromise todefine the quality standards of platelet concentrate for nontransfusion use (CPunT). Transfus. Apher. Sci., 2012, 47(2), 207-211.
2. Lynch, S.E.; Buser, D.; Hernandez, R.A.; Weber, H.P.; Stich, H.; Fox, C.H.; Williams, R.C. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs. J. Periodontol., 1991, 62(11), 710-716.
3. Yu, W.; Wang, J.; Yin, J. Platelet-rich plasma: A promisingproduct for treatment of peripheral nerve regeneration after nerve injury. Int. J. Neurosci., 2011, 121(4), 176-180.
4. Ferreira, C.F.; Carriel Gomes, M.C.; Filho, J.S.; Granjeiro, J.M.; Oliveira Simoes, C.M.; Magini Rde, S. Platelet-rich plasma influence on human osteoblasts growth. Clin. Oral. Implants Res., 2005, 16(4), 456-460.
5. Del Fabbro, M.; Bortolin, M.; Taschieri, S.; Weinstein, R. Isplatelet concentrate advantageous for the surgical treatment of periodontal diseases? A systematic review and meta-analysis. J. Periodontol., 2011, 82(8), 1100-1111.
6. Bertoldi, C.; Pinti, M.; Zaffe, D.; Cossarizza, A.; Consolo, U.; Ceccherelli, G.B. Morphologic, histochemical, and functional analysis of platelet-rich plasma activity on skeletal cultured cells. Transfusion, 2009, 49(8), 1728-1737.
7. Schlegel, K.A.; Donath, K.; Rupprecht, S.; Falk, S.; Zimmermann, R.; Felszeghy, E.; Wiltfang, J. De novo bone formation using bovine collagen and platelet-rich plasma. Biomaterials, 2004, 25(23), 5387-5393.
8. Tomoyasu, A.; Higashio, K.; Kanomata, K.; Goto, M.; Kodaira, K.; Serizawa, H.; Suda, T.; Nakamura, A.; Nojima, J.; Fukuda, T.; Katagiri, T. Platelet-rich plasma stimulates osteoblastic differentiation in the presence of BMPs. Biochem. Biophys. Res. Commun., 2007, 361 (1), 62-67.
9. Herrera, B.S.; Coimbra, L.S.; Bastos, A.S.; Teixeira, S.A.; Steffens, J.P.; Muscara, M.N.; Spolidorio, L.C. Platelet-rich plasma stimulates cytokine expression and alkaline phosphatase activity in osteoblast-derived osteosarcoma cells. Arch. Oral. Biol., 2012, 57(9), 1282-1289.
10. Iqbal, J.; Pepkowitz, S.H.; Klapper, E. Platelet-rich plasma for thereplenishment of bone. Curr. Osteoporos. Rep., 2011, 9(4), 258-263.
11. Borzini, P.; Balbo, V.; Mazzucco, L. Platelet concentrates for topi-cal use: bedside device and blood transfusion technology. Quality and versatility. Curr. Pharm. Biotech., 2012, 13(7), 1138-1144.
12. Pautke, C.; Schieker, M.; Tischer, T.; Kolk, A.; Neth, P.; Mutschler, W.; Milz, S. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res., 2004, 24(6), 3743-3748.
13. Clericuzio, M.; Burlando, B.; Gandini, G.; Tinello, S.; Ranzato, E.; Martinotti, S.; Cornara, L. Keratinocyte wound healing activity of galactoglycerolipids from the fern Ophioglossum vulgatum L. J. Nat. Med., 2014, 68(1), 31-37.
14. Ranzato, E.; Patrone, M.; Mazzucco, L.; Burlando, B. Plateletlysate stimulates wound repair of HaCaT keratinocytes. Br. J. Dermatol., 2008, 159(3), 537-545.
15. Clericuzio, M.; Tinello, S.; Burlando, B.; Ranzato, E.; Martinotti, S.; Cornara, L.; La Rocca, A. Flavonoid oligoglycosides from Ophioglossum vulgatum L. having wound healing properties. Planta Med., 2012, 78(15), 1639-1644.
16. Ranzato, E.; Boccafoschi, F.; Mazzucco, L.; Patrone, M.; Burlando, B. Role of ERK1/2 in platelet lysate-driven endothelial cell repair.J. Cell Biochem., 2010, 110(3), 783-93.
17. Ranzato, E.; Martinotti, S.; Burlando, B. Epithelial mesenchymaltransition traits in honey-driven keratinocyte wound healing: comparison among different honeys. Wound Repair Regen., 2012, 20(5), 778-85;
18. Martinotti, S.; Ranzato, E.; Parodi M.; Vitale M.; Burlando, B., Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells. Toxicol Appl Pharmacol., 2014, 274 (1), 35-41.
19. Martinotti, S.; Ranzato, E.; Burlando, B. In vitro screening of syn-ergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol. In Vitro, 2011, 25 (8), 1568-1574.
20. Greppi, N.; Mazzucco, L.; Galetti, G.; Bona, F.; Petrillo, E.; Smacchia, C.; Raspollini, E.; Cossovich, P.; Caprioli, R.; Borzini, P.; Rebulla, P.; Marconi, M. Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. Biologicals, 2011, 39(2), 73-80.
21. He, L.; Lin, Y.; Hu, X.; Zhang, Y.; Wu, H. A comparative study ofplatelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod., 2009, 108(5), 707-713.
22. Graziani, F.; Ivanovski, S.; Cei, S.; Ducci, F.; Tonetti, M.; Gabriele, M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin. Oral Implants Res., 2006, 17(2), 212-219.
23. Clausen, C.; Hermund, N.U.; Donatsky, O.; Nielsen, H.; Osther, K. Homologous activated platelets stimulate differentiation and proliferation of primary human bone cells. Cells Tissues Organs, 2006, 184(2), 68-75.
24. Slapnicka, J.; Fassmann, A.; Strasak, L.; Augustin, P.; Vanek, J. Effects of activated and nonactivated platelet-rich plasma on proliferation of human osteoblasts in vitro. J. Oral Maxillofac. Surg., 2008, 66(2), 297-301.
25. Sanchez, A.R.; Sheridan, P.J.; Kupp, L.I. Is platelet-rich plasma theperfect enhancement factor? A current review. Int. J. Oral Maxillofac. Implants, 2003, 18(1), 93-103.
26. Gerard, D.; Carlson, E.R.; Gotcher, J.E.; Jacobs, M. Effects ofplatelet-rich plasma at the cellular level on healing of autologous bone-grafted mandibular defects in dogs. J. Oral Maxillofac. Surg., 2007, 65(4), 721-727.
27. Bendinelli, P.; Matteucci, E.; Dogliotti, G.; Corsi, M.M.; Banfi, G.; Maroni, P.; Desiderio, M.A. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. J. Cell Physiol., 2010, 225(3), 757-766.
28. Goto, H.; Matsuyama, T.; Miyamoto, M.; Yonamine, Y.; Izumi, Y. Platelet-rich plasma/osteoblasts complex induces bone formation via osteoblastic differentiation following subcutaneous transplantation. J. Periodontal Res., 2006, 41(5), 455-462.
29. Kasten, P.; Vogel, J.; Beyen, I.; Weiss, S.; Niemeyer, P.; Leo, A.; Luginbuhl, R. Effect of platelet-rich plasma on the in vitro proliferation and osteogenic differentiation of human mesenchymal stem cells on distinct calcium phosphate scaffolds: the specific surface area makes a difference. J. Biomater Appl., 2008, 23(2), 169-188.
30. Kasten, P.; Vogel, J.; Luginbuhl, R.; Niemeyer, P.; Weiss, S.; Schneider, S.; Kramer, M.; Leo, A.; Richter, W. Influence of platelet-rich plasma on osteogenic differentiation of mesenchymal stem cells and ectopic bone formation in calcium phosphate ceramics. Cells Tissues Organs, 2006, 183(2), 68-79.
31. Okuda, K.; Kawase, T.; Momose, M.; Murata, M.; Saito, Y.; Suzuki, H.; Wolff, L.F.; Yoshie, H. Platelet-rich plasma contains high levels of platelet-derived growth factor and transforming growth factor-beta and modulates the proliferation of periodontally related cells in vitro. J. Periodontol., 2003, 74(6), 849-857.
32. Ogino, Y.; Ayukawa, Y.; Tsukiyama, Y.; Koyano, K. The effect ofplatelet-rich plasma on the cellular response of rat bone marrow cells in vitro. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod., 2005, 100(3), 302-307.
33. de Oliva, M.A.; Maximiano, W.M.; de Castro, L.M.; da Silva, P.E., Jr.; Fernandes, R.R.; Ciancaglini, P.; Beloti, M.M.; Nanci, A.; Rosa, A.L.; de Oliveira, P.T. Treatment with a growth factorprotein mixture inhibits formation of mineralized nodules inosteogenic cell cultures grown on titanium. J. Histochem. Cytochem., 2009, 57(3), 265-276.
34. Kawase, T.; Okuda, K.; Saito, Y.; Amizuka, N.; Suzuki, H.; Yoshie, H. Platelet-rich plasma provides nucleus for mineralization in cultures of partially differentiated periodontal ligament cells. In Vitro Cell Dev. Biol. Anim., 2005, 41(5-6), 171-176.
35. Notarnicola, A.; Tamma, R.; Moretti, L.; Panella, A.; Dell'endice, S.; Zallone, A.; Moretti, B. Effect of shock wave treatment on platelet-rich plasma added to osteoblast cultures. Ultrasound Med. Biol., 2011, 37(1), 160-168.
36. Nair, M.B.; Varma, H.K.; John, A. Platelet-rich plasma and fibringlue-coated bioactive ceramics enhance growth and differentiation of goat bone marrow-derived stem cells. Tissue Eng. Part A., 2009, 15(7), 1619-1631.
37. Shan, L.; Wang, G.; Zhang, C.; Zeng, B. Effect of variousconcentrations of platelet-rich plasma on osteogenic differentiation of skeletal muscle-derived stem cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2009, 23(8), 991-996.
38. Chen, L.; Lu, X.; Li, S.; Sun, Q.; Li, W.; Song, D. Sustaineddelivery of BMP-2 and platelet-rich plasma-released growth factors contributes to osteogenesis of human adipose-derived stem cells. Orthopedics, 2012, 35(9), e1402-1409.
39. Parsons, P.; Butcher, A.; Hesselden, K.; Ellis, K.; Maughan, J.; Milner, R.; Scott, M.; Alley, C.; Watson, J.T.; Horner, A. Plateletrich concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2 messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: a mode of action to enhance bone repair. J. Orthop. Trauma. 2008, 22(9), 595-604.
40. Hullinger, T.G.; Pan, Q.; Viswanathan, H.L.; Somerman, M.J. TGFbeta and BMP-2 activation of the OPN promoter: roles of smadand hox-binding elements. Exp. Cell Res., 2001, 262(1), 69-74.
41. Ogino, Y.; Ayukawa, Y.; Kukita, T.; Atsuta, I.; Koyano, K., Platelet-rich plasma suppresses osteoclastogenesis by promoting the secretion of osteoprotegerin. J. Periodontal. Res., 2009, 44(2), 217-224.
42. Cenni, E.; Avnet, S.; Fotia, C.; Salerno, M.; Baldini, N. Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood. J. Orthop. Res., 2010, 28(6), 792-797.
43. Komori, T.; Yagi, H.; Nomura, S.; Yamaguchi, A.; Sasaki, K.; Deguchi, K.; Shimizu, Y.; Bronson, R. T.; Gao, Y.H.; Inada, M.; Sato, M.; Okamoto, R.; Kitamura, Y.; Yoshiki, S.; Kishimoto, T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89(5), 755-764.
44. Enomoto, H.; Shiojiri, S.; Hoshi, K.; Furuichi, T.; Fukuyama, R.; Yoshida, C.A.; Kanatani, N.; Nakamura, R.; Mizuno, A.; Zanma, A.; Yano, K.; Yasuda, H.; Higashio, K.; Takada, K.; Komori, T. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/mice by RANKL transgene. J. Biol. Chem., 2003, 278(26), 23971-23977.
45. Drake, F.H.; Dodds, R.A.; James, I.E.; Connor, J.R.; Debouck, C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.J. Biol. Chem., 1996, 271(21), 12511-12516.
46. Weicht, B.; Maitz, P.; Kandler, B.; Fischer, M.B.; Watzek, G.; Gruber, R. Activated platelets positively regulate RANKLmediated osteoclast differentiation. J. Cell Biochem., 2007, 102(5), 1300-1307.